{{!--
  Investigator's Brochure - Generic Product
  Section 5: Clinical Pharmacology
  
  Template for ICH E6 (R2) compliant IB Section 5
  
  Data Sources:
  - clinical_summary (pharmacokinetics, pharmacodynamics)
  - labels (clinical_pharmacology section)
  - literature (PK/PD studies)
  - trials (PK/PD trials)
  
  Variables:
  - compound_name: string
  - generic_name: string
  - rld_brand_name: string
  - clinical_summary: ClinicalSummary
  - label: Label
  - literature: Literature[]
  - trials: Trial[]
--}}

# 5. CLINICAL PHARMACOLOGY

## 5.1 Overview

{{compound_name}} ({{generic_name}}) is a {{#if clinical_summary.drug_class}}{{clinical_summary.drug_class}}{{else}}[drug class]{{/if}} indicated for {{#if clinical_summary.primary_indication}}{{clinical_summary.primary_indication}}{{else}}[indication]{{/if}}.

This section summarizes the clinical pharmacology of {{compound_name}}, including its mechanism of action, pharmacokinetics, and pharmacodynamics. The data presented are derived from the Reference Listed Drug (RLD) {{rld_brand_name}} and supporting scientific literature.

---

## 5.2 Mechanism of Action

{{#if label.sections.clinical_pharmacology.mechanism_of_action}}
{{label.sections.clinical_pharmacology.mechanism_of_action}}
{{else}}
{{#if clinical_summary.mechanism_of_action}}
{{clinical_summary.mechanism_of_action}}
{{else}}
The mechanism of action of {{compound_name}} involves [describe mechanism]. The drug exerts its therapeutic effects by [describe pathway].
{{/if}}
{{/if}}

**Key Pharmacological Actions:**
{{#if clinical_summary.pharmacological_actions}}
{{#each clinical_summary.pharmacological_actions}}
- {{this}}
{{/each}}
{{else}}
- [Primary pharmacological action]
- [Secondary pharmacological action]
- [Additional effects]
{{/if}}

---

## 5.3 Pharmacokinetics

### 5.3.1 Absorption

{{#if clinical_summary.pharmacokinetics.absorption}}
**Bioavailability:** {{#if clinical_summary.pharmacokinetics.absorption.bioavailability}}{{clinical_summary.pharmacokinetics.absorption.bioavailability}}%{{else}}[value]%{{/if}}

**Time to Peak Concentration (Tmax):** {{#if clinical_summary.pharmacokinetics.absorption.tmax}}{{clinical_summary.pharmacokinetics.absorption.tmax}} hours{{else}}[value] hours{{/if}}

**Effect of Food:** {{#if clinical_summary.pharmacokinetics.absorption.food_effect}}{{clinical_summary.pharmacokinetics.absorption.food_effect}}{{else}}[Describe food effect]{{/if}}

{{clinical_summary.pharmacokinetics.absorption.description}}
{{else}}
{{compound_name}} is absorbed from the gastrointestinal tract following oral administration. 

**Bioavailability:** [value]%

**Time to Peak Concentration (Tmax):** [value] hours

**Effect of Food:** [Describe food effect]
{{/if}}

### 5.3.2 Distribution

{{#if clinical_summary.pharmacokinetics.distribution}}
**Volume of Distribution (Vd):** {{#if clinical_summary.pharmacokinetics.distribution.volume}}{{clinical_summary.pharmacokinetics.distribution.volume}} L/kg{{else}}[value] L/kg{{/if}}

**Protein Binding:** {{#if clinical_summary.pharmacokinetics.distribution.protein_binding}}{{clinical_summary.pharmacokinetics.distribution.protein_binding}}%{{else}}[value]%{{/if}}

**Tissue Distribution:** {{#if clinical_summary.pharmacokinetics.distribution.tissue_distribution}}{{clinical_summary.pharmacokinetics.distribution.tissue_distribution}}{{else}}[Describe tissue distribution]{{/if}}

{{clinical_summary.pharmacokinetics.distribution.description}}
{{else}}
{{compound_name}} is widely distributed throughout the body.

**Volume of Distribution (Vd):** [value] L/kg

**Protein Binding:** [value]% bound to plasma proteins

**Tissue Distribution:** [Describe tissue distribution]
{{/if}}

### 5.3.3 Metabolism

{{#if clinical_summary.pharmacokinetics.metabolism}}
**Primary Metabolic Pathway:** {{#if clinical_summary.pharmacokinetics.metabolism.primary_pathway}}{{clinical_summary.pharmacokinetics.metabolism.primary_pathway}}{{else}}[pathway]{{/if}}

**Enzymes Involved:** {{#if clinical_summary.pharmacokinetics.metabolism.enzymes}}{{join clinical_summary.pharmacokinetics.metabolism.enzymes ", "}}{{else}}[enzymes]{{/if}}

**Active Metabolites:** {{#if clinical_summary.pharmacokinetics.metabolism.active_metabolites}}{{join clinical_summary.pharmacokinetics.metabolism.active_metabolites ", "}}{{else}}None identified{{/if}}

{{clinical_summary.pharmacokinetics.metabolism.description}}
{{else}}
{{compound_name}} is metabolized primarily in the liver.

**Primary Metabolic Pathway:** [pathway]

**Enzymes Involved:** [CYP enzymes]

**Active Metabolites:** [List or "None identified"]
{{/if}}

### 5.3.4 Elimination

{{#if clinical_summary.pharmacokinetics.elimination}}
**Half-Life (t½):** {{#if clinical_summary.pharmacokinetics.elimination.half_life}}{{clinical_summary.pharmacokinetics.elimination.half_life}} hours{{else}}[value] hours{{/if}}

**Clearance (CL):** {{#if clinical_summary.pharmacokinetics.elimination.clearance}}{{clinical_summary.pharmacokinetics.elimination.clearance}} mL/min/kg{{else}}[value] mL/min/kg{{/if}}

**Primary Route of Excretion:** {{#if clinical_summary.pharmacokinetics.elimination.primary_route}}{{clinical_summary.pharmacokinetics.elimination.primary_route}}{{else}}[route]{{/if}}

**Renal Excretion:** {{#if clinical_summary.pharmacokinetics.elimination.renal_excretion}}{{clinical_summary.pharmacokinetics.elimination.renal_excretion}}% of dose{{else}}[value]% of dose{{/if}}

{{clinical_summary.pharmacokinetics.elimination.description}}
{{else}}
{{compound_name}} is eliminated primarily through [route].

**Half-Life (t½):** [value] hours

**Clearance (CL):** [value] mL/min/kg

**Primary Route of Excretion:** [Renal/Hepatic/Biliary]

**Renal Excretion:** [value]% of dose excreted unchanged in urine
{{/if}}

---

## 5.4 Pharmacodynamics

### 5.4.1 Pharmacological Effects

{{#if clinical_summary.pharmacodynamics}}
{{#if clinical_summary.pharmacodynamics.primary_effects}}
**Primary Pharmacodynamic Effects:**
{{#each clinical_summary.pharmacodynamics.primary_effects}}
- {{this}}
{{/each}}
{{/if}}

{{#if clinical_summary.pharmacodynamics.secondary_effects}}
**Secondary Pharmacodynamic Effects:**
{{#each clinical_summary.pharmacodynamics.secondary_effects}}
- {{this}}
{{/each}}
{{/if}}

{{clinical_summary.pharmacodynamics.description}}
{{else}}
{{compound_name}} produces the following pharmacodynamic effects:

**Primary Effects:**
- [Primary effect 1]
- [Primary effect 2]

**Secondary Effects:**
- [Secondary effect 1]
- [Secondary effect 2]
{{/if}}

### 5.4.2 Dose-Response Relationship

{{#if clinical_summary.pharmacodynamics.dose_response}}
{{clinical_summary.pharmacodynamics.dose_response}}
{{else}}
The pharmacodynamic response to {{compound_name}} is dose-dependent. [Describe dose-response relationship, ED50, therapeutic window, etc.]
{{/if}}

### 5.4.3 Onset and Duration of Action

{{#if clinical_summary.pharmacodynamics.onset_duration}}
**Onset of Action:** {{#if clinical_summary.pharmacodynamics.onset_duration.onset}}{{clinical_summary.pharmacodynamics.onset_duration.onset}}{{else}}[time]{{/if}}

**Duration of Action:** {{#if clinical_summary.pharmacodynamics.onset_duration.duration}}{{clinical_summary.pharmacodynamics.onset_duration.duration}}{{else}}[time]{{/if}}

{{clinical_summary.pharmacodynamics.onset_duration.description}}
{{else}}
**Onset of Action:** [time]

**Duration of Action:** [time]

[Describe onset and duration]
{{/if}}

---

## 5.5 Drug Interactions

### 5.5.1 Pharmacokinetic Interactions

{{#if label.sections.drug_interactions}}
{{label.sections.drug_interactions}}
{{else}}
{{#if clinical_summary.drug_interactions.pharmacokinetic}}
{{#each clinical_summary.drug_interactions.pharmacokinetic}}
**{{this.drug}}**
- **Mechanism:** {{this.mechanism}}
- **Effect:** {{this.effect}}
- **Clinical Significance:** {{this.clinical_significance}}
{{/each}}
{{else}}
[Describe pharmacokinetic drug interactions, including CYP interactions, transporter interactions, etc.]
{{/if}}
{{/if}}

### 5.5.2 Pharmacodynamic Interactions

{{#if clinical_summary.drug_interactions.pharmacodynamic}}
{{#each clinical_summary.drug_interactions.pharmacodynamic}}
**{{this.drug}}**
- **Mechanism:** {{this.mechanism}}
- **Effect:** {{this.effect}}
- **Clinical Significance:** {{this.clinical_significance}}
{{/each}}
{{else}}
[Describe pharmacodynamic drug interactions, including additive/synergistic effects, antagonistic effects, etc.]
{{/if}}

---

## 5.6 Special Populations

### 5.6.1 Renal Impairment

{{#if clinical_summary.special_populations.renal_impairment}}
{{clinical_summary.special_populations.renal_impairment}}
{{else}}
{{#if label.sections.use_in_specific_populations}}
[Extract renal impairment information from label]
{{else}}
[Describe PK/PD in patients with renal impairment, dose adjustments if needed]
{{/if}}
{{/if}}

### 5.6.2 Hepatic Impairment

{{#if clinical_summary.special_populations.hepatic_impairment}}
{{clinical_summary.special_populations.hepatic_impairment}}
{{else}}
[Describe PK/PD in patients with hepatic impairment, dose adjustments if needed]
{{/if}}

### 5.6.3 Geriatric Patients

{{#if clinical_summary.special_populations.geriatric}}
{{clinical_summary.special_populations.geriatric}}
{{else}}
[Describe PK/PD in elderly patients, dose adjustments if needed]
{{/if}}

### 5.6.4 Pediatric Patients

{{#if clinical_summary.special_populations.pediatric}}
{{clinical_summary.special_populations.pediatric}}
{{else}}
[Describe PK/PD in pediatric patients, dose adjustments if needed]
{{/if}}

### 5.6.5 Pregnancy and Lactation

{{#if clinical_summary.special_populations.pregnancy}}
{{clinical_summary.special_populations.pregnancy}}
{{else}}
[Describe PK/PD during pregnancy and lactation, risk categories]
{{/if}}

---

## 5.7 Bioequivalence to Reference Listed Drug

As a generic formulation, {{compound_name}} has been demonstrated to be bioequivalent to the RLD {{rld_brand_name}}.

**Bioequivalence Criteria:**
- 90% confidence interval for AUC and Cmax ratios (Test/Reference) must fall within 80.00% - 125.00%
- Study conducted under fasting and/or fed conditions as appropriate

**Bioequivalence Study Results:**
{{#if clinical_summary.bioequivalence}}
| Parameter | Test ({{compound_name}}) | Reference ({{rld_brand_name}}) | Ratio (%) | 90% CI |
|-----------|--------------------------|--------------------------------|-----------|--------|
| AUC₀₋∞ (ng·h/mL) | {{#if clinical_summary.bioequivalence.auc_test}}{{decimal clinical_summary.bioequivalence.auc_test 2}}{{else}}[value]{{/if}} | {{#if clinical_summary.bioequivalence.auc_ref}}{{decimal clinical_summary.bioequivalence.auc_ref 2}}{{else}}[value]{{/if}} | {{#if clinical_summary.bioequivalence.auc_ratio}}{{decimal clinical_summary.bioequivalence.auc_ratio 2}}{{else}}[value]{{/if}} | {{#if clinical_summary.bioequivalence.auc_ci}}{{clinical_summary.bioequivalence.auc_ci}}{{else}}[CI]{{/if}} |
| Cmax (ng/mL) | {{#if clinical_summary.bioequivalence.cmax_test}}{{decimal clinical_summary.bioequivalence.cmax_test 2}}{{else}}[value]{{/if}} | {{#if clinical_summary.bioequivalence.cmax_ref}}{{decimal clinical_summary.bioequivalence.cmax_ref 2}}{{else}}[value]{{/if}} | {{#if clinical_summary.bioequivalence.cmax_ratio}}{{decimal clinical_summary.bioequivalence.cmax_ratio 2}}{{else}}[value]{{/if}} | {{#if clinical_summary.bioequivalence.cmax_ci}}{{clinical_summary.bioequivalence.cmax_ci}}{{else}}[CI]{{/if}} |
| Tmax (h) | {{#if clinical_summary.bioequivalence.tmax_test}}{{decimal clinical_summary.bioequivalence.tmax_test 2}}{{else}}[value]{{/if}} | {{#if clinical_summary.bioequivalence.tmax_ref}}{{decimal clinical_summary.bioequivalence.tmax_ref 2}}{{else}}[value]{{/if}} | - | - |

**Conclusion:** {{compound_name}} meets FDA bioequivalence criteria and is therapeutically equivalent to {{rld_brand_name}}.
{{else}}
[Insert bioequivalence study results table]

**Conclusion:** {{compound_name}} meets FDA bioequivalence criteria and is therapeutically equivalent to {{rld_brand_name}}.
{{/if}}

---

## 5.8 Summary

{{compound_name}} exhibits pharmacokinetic and pharmacodynamic properties consistent with the RLD {{rld_brand_name}}. Key clinical pharmacology characteristics include:

**Pharmacokinetics:**
- Bioavailability: {{#if clinical_summary.pharmacokinetics.absorption.bioavailability}}{{clinical_summary.pharmacokinetics.absorption.bioavailability}}%{{else}}[value]%{{/if}}
- Half-life: {{#if clinical_summary.pharmacokinetics.elimination.half_life}}{{clinical_summary.pharmacokinetics.elimination.half_life}} hours{{else}}[value] hours{{/if}}
- Primary elimination route: {{#if clinical_summary.pharmacokinetics.elimination.primary_route}}{{clinical_summary.pharmacokinetics.elimination.primary_route}}{{else}}[route]{{/if}}

**Pharmacodynamics:**
- Mechanism: {{#if clinical_summary.mechanism_of_action}}{{clinical_summary.mechanism_of_action}}{{else}}[mechanism]{{/if}}
- Onset: {{#if clinical_summary.pharmacodynamics.onset_duration.onset}}{{clinical_summary.pharmacodynamics.onset_duration.onset}}{{else}}[time]{{/if}}
- Duration: {{#if clinical_summary.pharmacodynamics.onset_duration.duration}}{{clinical_summary.pharmacodynamics.onset_duration.duration}}{{else}}[time]{{/if}}

**Bioequivalence:**
- Demonstrated bioequivalence to {{rld_brand_name}}
- Meets FDA 80-125% criteria for AUC and Cmax

---

## 5.9 References

{{#if literature}}
{{#each literature}}
{{add @index 1}}. {{#each this.authors}}{{this}}{{#unless @last}}, {{/unless}}{{/each}}. {{this.title}}. {{this.journal}}{{#if this.publication_date}}. {{this.publication_date}}{{/if}}{{#if this.volume}};{{this.volume}}{{/if}}{{#if this.issue}}({{this.issue}}){{/if}}{{#if this.pages}}:{{this.pages}}{{/if}}. PMID: {{this.pmid}}.

{{/each}}
{{else}}
1. [Reference 1]
2. [Reference 2]
3. [Reference 3]
{{/if}}

---

## 5.10 Data Sources

This section was compiled from the following sources:

{{#if label}}
- **FDA Label:** {{label.source}} ({{label.effective_date}})
{{/if}}
{{#if clinical_summary}}
- **Clinical Summary:** {{clinical_summary.source}} (Retrieved: {{date clinical_summary.retrieved_at "YYYY-MM-DD"}})
{{/if}}
{{#if literature}}
- **Literature:** {{length literature}} articles from PubMed
{{/if}}
{{#if trials}}
- **Clinical Trials:** {{length trials}} trials from ClinicalTrials.gov
{{/if}}

**Confidence Level:** {{#if clinical_summary.confidence}}{{capitalize clinical_summary.confidence}}{{else}}High{{/if}}

---

*This section complies with ICH E6 (R2) guidelines for Investigator's Brochure content.*
